

07/56977

8/13/90

Group Art Unit

Examiner

PRICESSEUDY

JUL 19 1999

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- (A) referred to in United States Patent Number 5623065 column _____
- (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.14
Application No. _____ file _____ on page _____
paper number _____
- (C) an application that claims the benefit of the filing date of an application that is open to
inspection, i.e., Application No. _____ file _____
- (D) an application in which the applicant has filed an authorization to lay open the application to the public.

Please direct any correspondence concerning this request to the following address:

5/6/99

Date

Signature

Billy Mullenay

Type or printed name

FOR PTO USE ONLY

Approved by (initials)

Unit: _____

Successive patent applications, the continuation or divisional of such applications, and applications for reissue of any patent or patent application filed by the same inventor or joint inventors in the same patent office, may be filed in the same file. The filing of such an application does not constitute a abandonment of the original application. The filing of such an application does not constitute a abandonment of the original application.



US005623065A

United States Patent

[19]

Cook et al.

[11] Patent Number: 5,623,065

[45] Date of Patent: Apr. 22, 1997

[54] GAPPED 2' MODIFIED OLIGONUCLEOTIDES

[75] Inventors: Phillip D. Cook, Vista; Brett P. Monia, Carlsbad, both of Calif.

[73] Assignee: Isis Pharmaceuticals, Inc., Carlsbad, Calif.

[21] Appl. No.: 244,993

[22] PCT Filed: Dec. 23, 1992

[86] PCT No.: PCT/US92/11339

§ 371 Date: Jun. 21, 1994

§ 102(e) Date: Jun. 21, 1994

[87] PCT Pub. No.: WO93/11339

PCT Pub. Date: Jul. 8, 1993

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 814,961, Dec. 24, 1991, abandoned, and Ser. No. 566,977, Aug. 13, 1990, abandoned.

[51] Int. Cl. 6 C07H 21/00; C07H 21/02; C07H 21/04

[52] U.S. Cl. 536/23.1; 536/23.2; 536/23.5; 536/23.51; 536/23.52; 536/23.53; 536/25.1; 536/25.2; 435/91.1; 435/91.2; 435/91.5; 935/6; 935/9; 935/10

[58] Field of Search 514/44; 536/23.1, 536/23.2, 23.5, 23.51, 23.52, 23.53, 25.1, 25.2; 435/91.1, 91.2, 91.4, 91.5; 935/9, 6, 10

[56] References Cited

U.S. PATENT DOCUMENTS

| | | | |
|-----------|---------|-----------------------|-----------|
| 4,867,187 | 9/1989 | Duck | 435/6 |
| 4,908,307 | 3/1990 | Rodland et al. | 435/6 |
| 5,013,830 | 5/1991 | Ohtsuka et al. | 536/25.1 |
| 5,034,506 | 7/1991 | Summerton et al. | 528/391 |
| 5,134,066 | 7/1992 | Rogers et al. | 435/91.3 |
| 5,149,797 | 9/1992 | Pederson et al. | 536/23.1 |
| 5,220,007 | 6/1993 | Pederson et al. | 536/23.1 |
| 5,256,775 | 10/1993 | Froehler | 536/25.6 |
| 5,366,878 | 11/1994 | Pederson et al. | 435/91.3 |
| 5,403,711 | 4/1995 | Walder et al. | 435/6 |
| 5,466,786 | 11/1995 | Buhr et al. | 536/26.26 |

FOREIGN PATENT DOCUMENTS

| | | |
|------------|---------|----------------------|
| 2017369 | 11/1990 | Canada . |
| 260032 | 8/1987 | European Pat. Off. . |
| 365627B1 | 3/1989 | European Pat. Off. . |
| 0339842 | 4/1989 | European Pat. Off. . |
| 0339330 | 11/1990 | European Pat. Off. . |
| 3915462 | 9/1990 | Germany . |
| 4110085 | 10/1992 | Germany . |
| 3-240795 | of 1991 | Japan . |
| 89/05358 | 6/1989 | WIPO . |
| WO90/15814 | 6/1990 | WIPO . |
| WO91/06556 | 10/1990 | WIPO . |
| WO91/15499 | 4/1991 | WIPO . |
| WO91/12323 | 8/1991 | WIPO . |
| WO94/02498 | 2/1994 | WIPO . |
| WO92/07065 | 9/1994 | WIPO . |

OTHER PUBLICATIONS

Block et al. 1988 Gene 72, 349-360.

Cormier et al. 1988 Nuc. Acids Res. 16(10), 4583-4594.

Uhlmann et al. 1990 Chemical Reviews 90(4), 544-584.

Ikehara et al. 1977 Nuc. Acids Res. 4(12): 4249-4260.

Berkowitz et al. 1973 J. Medicinal Chemistry, 16(2): 813-814.

Kawasaki et al. 1991 (Jan.) "Synthesis and Biophysical Studies of 2'-dRIBO-F Modified Oligonucleotides", Conference on Nucleic Acid Therapeutics, Clearwater, FL.

Agrawal, S. et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus" Proc. Natl. Acad. Sci. USA 1988 85, 7079-7083.

Augustyns, et. al., "Influence of the Incorporation of (S)-9-(3,4-dihydroxy-butyl)Adenine on the Enzymatic Stability and Base-Pairing Properties of Oligodeoxynucleotides" Nucleic Acids Research 1991, 19, 2587-2593.

Beaton, et. al., Chapter 5, Synthesis of oligonucleotide phosphorodithioates, p. 109, *Oligonucleotides and Analogs, A Practical Approach*, Eckstein, F., Ed.; The Practical Approach Series, IRL Press, New York, 1991, pp. 109-135.

Borthwick, et al., "Synthesis of Chiral Carbocyclic Nucleosides" Tetrahedron 1992, 48, 571-623.

Brill et al., "Synthesis of Deoxydinucleoside Phosphorodithioates", J. Am. Chem. Soc. 1991 113, 3972-3980.

Cohen in *Oligonucleotides: Antisense Inhibitors of Gene Expression*, CRC Press, Inc., Boca Raton, FL (1989), pp. 1-255.

Dagle et al., "Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages", Nucleic Acids Research 1991 19, 1805-1810.

Dagle et al., "Targeted degradation of mRNA in *Xenopus* oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis", Nucleic Acids Research 1990 18, 4751-4757.Dagle et al., "Pathways of Degradation and Mechanism of Action of Antisense Oligonucleotides in *Xenopus laevis* Embryos", Antisense Research and Development 1991 1, 11-20.

Debart et al., "Intermolecular Radical C-C Bond Formation: Synthesis of a Novel Dinucleoside Linker for Non-anionic Antisense Oligonucleosides", Tetra. Lett. 1992 33, 2645-2648.

(List continued on next page.)

Primary Examiner—Christopher S. F. Low
Attorney, Agent, or Firm—Woodcock Washburn Kurtz Mackiewicz & Norris

[57] ABSTRACT

Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics.